What is Rapport Therapeutics, Inc. Common Stock's Shariah compliance score?

Rapport Therapeutics, Inc. Common Stock (RAPP) has a Shariah compliance score of 82/100 (Grade: A, Very Good) based on AAOIFI screening standards. Scores above 70 typically indicate strong compliance. The score factors in business activity screening and financial ratio analysis including debt levels, interest-bearing deposits, and prohibited income percentages. View the full breakdown at HalalScreener.app.

Does Rapport Therapeutics, Inc. Common Stock pass AAOIFI screening?

Rapport Therapeutics, Inc. Common Stock (RAPP) passes AAOIFI Shariah screening. AAOIFI requires: (1) no primary involvement in prohibited activities like alcohol, gambling, or conventional banking, (2) debt-to-market-cap below 30% (RAPP: 0.5%), (3) interest-bearing deposits below 30%, and (4) prohibited income below 5%. HalalScreener provides free AAOIFI screening for 6,200+ stocks at halalscreener.app.

How much purification is needed for Rapport Therapeutics, Inc. Common Stock stock?

Muslim investors purify the portion of dividends and realized gains that comes from non-permissible income by donating it to charity. HalalScreener's purification calculator at halalscreener.app/en/purification computes the exact percentage and amount for Rapport Therapeutics, Inc. Common Stock (RAPP) using the latest financial data.

Where can I screen Rapport Therapeutics, Inc. Common Stock for Shariah compliance for free?

HalalScreener (halalscreener.app) offers free Shariah compliance screening for Rapport Therapeutics, Inc. Common Stock (RAPP) and 5,100+ other US-listed stocks, ETFs, and 100+ cryptocurrencies. The screening uses AAOIFI Standard No. 21 and shows the verdict, compliance grade, score, and debt ratio free. No credit card or signup required for basic screening; the full ratio breakdown is part of Pro. HalalScreener also includes an AI Islamic Scholar for follow-up questions about RAPP's compliance across different madhabs (Hanafi, Shafi'i, Maliki, Hanbali, Ja'fari).

RAPP: Is Rapport Therapeutics, Inc. Common Stock Halal?

Rapport Therapeutics, Inc. Common Stock

NASDAQHealthcareUS

$48.42

+2.11%

Market Cap: 2.3B

Compliance Status

Halal

Screened on Sep 1, 2026 · AAOIFI Standard 21

Very Good

82Score

Is Rapport Therapeutics, Inc. Common Stock (RAPP) halal? Halal. Based on AAOIFI screening, Rapport Therapeutics, Inc. Common Stock passes both qualitative (business activity) and quantitative (financial ratio) screens with a compliance score of 82/100 (Grade: A).

Quote this verdict

HalalScreener rates Rapport Therapeutics, Inc. Common Stock (RAPP) Halal, 82/100, grade A under AAOIFI Standard 21, screened Sep 1, 2026. Source: https://halalscreener.app/en/stock/RAPP

AvoidBorderlineClean

Business activity

What the company sells is permissible.

Passed

Company debt

Well clear of the limit

How much the company borrows, compared to its total value. AAOIFI allows up to 30%.

0.5% of 30.0% limit

What this means for you

You can own RAPP

It passes both the business activity and financial ratio screens under AAOIFI Standard 21.

Purification amount is Pro

We have screened RAPP's prohibited income, but the exact share you would need to purify is part of Pro.

About Rapport Therapeutics, Inc. Common Stock

Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder. The company's pipeline further includes RAP-199, another molecule targeting TARPy8, which boasts distinct chemical and pharmacokinetic profiles. Moreover, Rapport is advancing several nicotinic acetylcholine receptor (nAChR) programs, such as an a6 nAChR therapy for chronic pain and an a9a10 nAChR treatment intended for hearing impairments. Formed in 2022 under the initial name Precision Neuroscience NewCo, Inc., the company adopted its current identity as Rapport Therapeutics, Inc. in October 2022, and its operations are based in Boston, Massachusetts.

Sector: Healthcare · Industry: Biotechnology

Shariah Compliance Status

AAOIFI Standard 21Updated Sep 1, 2026

Compliance History

Halalnow
since Aug 2026
Under Review
until the change above
Not Halal
until the change above

Tracked since May 2026. Updates automatically on each re-screen.

Fiscal: FY 2025Data source: FMP

More Healthcare Stocks

JNJ

Johnson & Johnson

UNH

UnitedHealth Group Incorporated

ABBV

AbbVie Inc.

PFE

Pfizer Inc.

LLY

Eli Lilly and Company

A+

MRK

Merck & Co., Inc.

Free · No credit card required

Track RAPP and 6,200+ stocks with AI insights

Create your free account to unlock AI-powered compliance analysis, track your portfolio, calculate purification, and get unlimited AAOIFI screening.

Get Started Free Browse Screener

6,200+ assets AAOIFI standards Free watchlist

Frequently Asked Questions

Is Rapport Therapeutics, Inc. Common Stock (RAPP) halal to invest in?

Based on AAOIFI Standard 21 screening, Rapport Therapeutics, Inc. Common Stock (RAPP) is rated Halal with a compliance grade of A (Very Good). It passes both the business activity screen (no primary involvement in prohibited sectors) and the quantitative financial ratio screen (debt, interest deposits, and prohibited income all below AAOIFI thresholds).

Why did Rapport Therapeutics, Inc. Common Stock get a A compliance rating?

Rapport Therapeutics, Inc. Common Stock (RAPP) received a grade of A (Very Good) based on three AAOIFI Standard 21 financial ratios: debt-to-market-cap of 0.5% (limit 30%). The grade reflects the margin of safety across all three ratios relative to their thresholds.

What could change Rapport Therapeutics, Inc. Common Stock's Shariah verdict?

Rapport Therapeutics, Inc. Common Stock's verdict is re-evaluated at each annual re-screen. Three events could change it: (1) the debt-to-market-cap ratio crossing 30%, typically from new debt issuance or a major drop in share price; (2) interest-bearing deposits exceeding 30% of market cap; or (3) prohibited revenue (alcohol, gambling, conventional finance, etc.) exceeding 5% of total revenue. Verdict flips are tracked in the compliance history section above.

How often is Rapport Therapeutics, Inc. Common Stock re-screened for Shariah compliance?

Rapport Therapeutics, Inc. Common Stock (RAPP) is re-screened annually using the most recent full-year financial data from SEC filings. HalalScreener also triggers an on-demand re-screen whenever the stored data is more than 7 days old, ensuring the ratios reflect the latest available financial statements. Last screened: Sep 1, 2026.

Screened according to AAOIFI Standard No. 21 · For informational purposes only. Consult a qualified Islamic finance advisor before investing.

Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.